Therefore, the effect of TME on CD8+ T cells in HBV+HCC requires further in‐depth studies, as well as the mechanisms of various HCC therapeutic strategies need to be explored and validated by further research and clinical trials. Here, CD8A is linked to hepatocellular carcinoma.